close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by PerkinElmer, Inc.

< Previous 1 2 Next >
PerkinElmer Board Declares Quarterly Dividend
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
PerkinElmer Updates Fourth Quarter Outlook; To Hold Earnings Call on Tuesday, February 1, 2022
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
PerkinElmer to Present Virtually at J.P. Morgan Healthcare Conference
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
PerkinElmer Launches NEXTFLEX Variant-Seq SARS-CoV-2 Kit v2 to Strengthen SARS-CoV-2 Surveillance
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
PerkinElmer Confirms That Omicron Variant Does Not Impact SARS-CoV-2 Detection Capability of its RT-PCR Assays
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
PerkinElmer Launches Cloud Based Solution to Enable Remote Lab Management
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer to Present at Evercore ISI HealthCONx Conference 2021
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
PerkinElmer to Present at 2021 Stifel Healthcare Conference
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
PerkinElmer Announces Financial Results for the Third Quarter of 2021
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
PerkinElmer Releases 2021 Corporate Social Responsibility Report
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
PerkinElmer Board Declares Quarterly Dividend
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
PerkinElmer Signals Research Suite Platform Integrates Scientific Data Silos and Enhances Collaboration for R&D Teams
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Schedules Earnings Call for Tuesday, November 2, 2021
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
PerkinElmer Receives FDA Emergency Use Authorization for Respiratory SARS-CoV-2 Panel
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
EUROIMMUN Anti-SARS-CoV-2 S1 Curve ELISA Receives FDA Emergency Use Authorization
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
PerkinElmer Prices Offering of Senior Notes
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
PerkinElmer to Present at 2021 Baird Global Healthcare Conference
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
PerkinElmer Expands Automated Mycotoxin Detection Kits Portfolio to Include All Major Mycotoxins
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Expands KRAS Oncology Drug Discovery Assays with New Ready-to-Use AlphaLISA Kits
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer to Acquire Antibody and Reagent Leader BioLegend
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
PerkinElmer Board Declares Quarterly Dividend
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
PerkinElmer Provides Update on Second Quarter Performance and Schedules Earnings Call for Wednesday, July 28, 2021
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
PerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader SIRION Biotech
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
PerkinElmer Supports JUMP-CP Consortium Creating World’s Largest, Public Cell Painting Dataset
From PerkinElmer, Inc.
Via Business Wire
Welsh Lighthouse Laboratory Extends Contract with PerkinElmer for its COVID-19 Solutions
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer to Acquire In-Vitro Diagnostics Company Immunodiagnostic Systems Holdings PLC
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
PerkinElmer Expands Cell Biology Leadership with Agreement to Acquire Nexcelom Bioscience
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
PerkinElmer to Host Virtual Investor and Analyst Day
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
PerkinElmer Announces Financial Results for the First Quarter of 2021
From PerkinElmer, Inc.
Via Business Wire
Tickers PKI
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today